New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 3, 2012
08:01 EDTEFX, CSCCSC to sell credit services unit for $1B to Equifax
As part of its transformation initiative to rebalance its portfolio of services and focus on next-generation technology solutions and services, CSC (CSC) has reached a definitive agreement with Equifax (EFX) for the sale of its credit services unit for $1B in cash. The after-tax proceeds from the sale of the business will be approximately $750 - $800 million based on preliminary plans. CSC intends to use $300M-$400M to repurchase shares, contribute $300M-$400M to its pension plans and apply the remainder to general corporate purposes. The companies anticipate closing of the transaction by the end of the calendar year after concluding regulatory reviews. This deal marks CSC’s second divestiture in six weeks.
News For CSC;EFX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 21, 2015
05:50 EDTEFXFair Isaac upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Fair Isaac to Overweight citing growth at Scores, software sales momentum and the company's continued buybacks. The firm raised its price target for shares to $85 from $65. Barclays coupled the upgrade with a downgrade of Dun & Bradstreet (DNB) to Underweight. It also keeps an Overweight rating on Equifax (EFX).
January 20, 2015
10:03 EDTCSCCSC awarded follow-on healthcare contract worth up to $90M
CSC announced that its company, DynPort Vaccine Company, received a follow-on contract to continue supporting the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. Valued at up to $90M, the award is a 10-year Indefinite Delivery/Indefinite Quantity contract to support and conduct Phase 1 clinical trials of infectious disease therapeutics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use